Tasquinimod-d3
Product Specifications
UNSPSC Description
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor[1][2][3].
Target Antigen
HDAC; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Cell Cycle/DNA Damage;Epigenetics;Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.34
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N(C1=CC=C(C=C1)C(F)(F)F)C([2H])([2H])[2H])C2=C(C3=C(C=CC=C3OC)N(C2=O)C)O
Molecular Weight
409.37
References & Citations
[1]Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386-99.|[2]Olsson A, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107.|[3]Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Sep 30;5(18):8093-106.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Clinical Information
No Development Reported
CAS Number
1416701-99-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
